SS-31
Also known as: Elamipretide
SS-31 (elamipretide) is a mitochondria-targeted tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) developed by Hazel Szeto (Cornell) and clinically advanced by Stealth BioTherapeutics. It concentrates in the inner mitochondrial membrane by binding cardiolipin. In September 2025, the FDA granted accelerated approval to elamipretide (brand name FORZINITY) as the first therapy for Barth syndrome — the first FDA-approved mitochondria-targeted drug. It remains investigational for other indications.
Pricing for SS-31
Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.
COAs for SS-31
62 third-party tests across 14 vendors. Each card links to the full report.
For
SS-31
by Ion Peptide· batch 2S10-05042026
For
SS-31
by Peptidegurus· batch cmojgr89m002r9grxu1x2sttx
For
SS-31
by Peptide Plugs· batch 121-A-D
For
SS-31
by Forge Performance Co.· batch Blue Top
For
SS-31
by Qihang Peptide· batch 3
For
SS-31
by Glacier Aminos· batch MTP10GA-03
For
SS-31
by Mile High Compounds· batch SS3-010-MH-04
For
SS-31
by Qihang Peptide· batch 2
For
SS-31
by Peptide Supply Co.· batch PSCSS3150001
For
SS-31
by Peptide Partners· batch SS202602
For
SS-31
by Ion Peptide· batch SS3110-02032026
For
SS-31
by Ion Peptide· batch C3150-02272026
For
SS-31
by Ion Peptide· batch SS310-011326
For
SS-31
by Ion Peptide· batch SS-31-10-122925
For
SS-31
by Ion Peptide· batch SS31-12082025
For
SS-31
by Ion Peptide· batch SS3-L-1125
For
SS-31
by BioLongevity Labs· batch cmojb74wp018pkirx3aovkfuu
For
SS-31
by BioLongevity Labs· batch 26-3-45937
For
SS-31
by Ion Peptide· batch SS5-1025
For
SS-31
by Peptide Partners· batch SY20250806
For
SS-31
by Verified Peptides· batch cmojb5o2600xkkirx15ijd379
For
SS-31
by Verified Peptides· batch 06-25-0530E
For
SS-31
by Profound Aminos· batch cmojb88i801hqkirxb9x1uu7r
For
SS-31
by Verified Peptides· batch 06-25-0530E
14 citations indexed for SS-31
Study · 2026
Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function
Membrane binding and aggregation properties of α-synuclein are closely associated with Parkinson's disease and a class of related syndromes named as synucleinopathy.
animal · 2026
Elamipretide (SS-31) promotes recovery by preserving mitochondrial bioenergetics and neural remodeling after spinal cord injury
Spinal cord injury (SCI) induces secondary damage characterized by mitochondrial dysfunction, oxidative stress, and apoptosis, which collectively impede neurological recovery. Elamipretide (SS-31) is a mitochondria-targeting peptide with potential neuroprotective effects.
animal · 2026
SLC25A28 Ameliorates Hyperoxic Lung Injury by Improving Mitochondrial Oxidative Phosphorylation in Alveolar Epithelial Cells
Mitochondrial dysfunction plays a central role in the pathogenesis of bronchopulmonary dysplasia (BPD). Solute carrier family 25 member 28 (SLC25A28) is an iron transporter located in the inner mitochondrial membrane. In this study, we aimed to explore the role and underlying molecular mechanisms of SLC25A28 in BPD.
Study · 2026
SS-31 improves the quality of maternally aged oocytes by ameliorating mitochondrial function and metabolism
Study · 2026
Mechanisms of Anti-Oxidants, N-Acetylcysteine and Elamipretide (SS-31), on Ozone-Induced Airway Hyperresponsiveness and Mucus Hypersecretion
Background Ozone (O₃) exposure induces acute airway injury characterized by airway hyperresponsiveness (AHR) and airway mucus hypersecretion (AMH). Oxidative stress and mitochondria-derived reactive oxygen species (mtROS) are key contributors.
Study · 2026
Restoring cardiolipin homeostasis mitigates cerebral ischemia-reperfusion injury by suppressing ATG5-mediated neuronal autophagy-dependent ferroptosis
Introduction Cardiolipins (CLs) are mitochondria-specific phospholipids critically involved in neurological disorders. However, their roles in cerebral ischemia/reperfusion (I/R) injury remains largely underexplored.